Pre-clinical data show that PD-1 blockade (nivolumab) enhanced CAR-iNKT proliferation, cytokine production (IL-2, TNF-α, IFN-γ, and granzyme B) and effectively reversed CAR-iNKT exhaustion upon tumor rechallenge, translating into deeper tumor control (149). Here, TNF is linked to neoplasm.